-$0.16 EPS Expected for ANCHIANO THERAP/S (NASDAQ:ANCN) This Quarter

Brokerages forecast that ANCHIANO THERAP/S (NASDAQ:ANCN) will post earnings per share of ($0.16) for the current quarter, according to Zacks. Zero analysts have issued estimates for ANCHIANO THERAP/S’s earnings. The company is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that ANCHIANO THERAP/S will report full-year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.57) to ($0.80). For the next year, analysts expect that the business will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.97) to ($0.64). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow ANCHIANO THERAP/S.

ANCHIANO THERAP/S (NASDAQ:ANCN) last issued its earnings results on Monday, August 5th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.11.



A number of research firms have recently weighed in on ANCN. Robert W. Baird began coverage on ANCHIANO THERAP/S in a research report on Tuesday, May 28th. They set an “outperform” rating and a $12.00 price objective on the stock. Zacks Investment Research upgraded shares of ANCHIANO THERAP/S from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research report on Friday. Finally, ValuEngine upgraded shares of ANCHIANO THERAP/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Five analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $10.42.

Several large investors have recently modified their holdings of the company. FMR LLC bought a new stake in shares of ANCHIANO THERAP/S during the first quarter valued at approximately $288,000. Kennedy Capital Management Inc. acquired a new stake in shares of ANCHIANO THERAP/S in the first quarter valued at approximately $1,359,000. Delek Group Ltd. acquired a new stake in shares of ANCHIANO THERAP/S in the first quarter valued at approximately $176,000. Finally, Meitav Dash Investments Ltd. acquired a new stake in shares of ANCHIANO THERAP/S in the first quarter valued at approximately $177,000. 11.17% of the stock is currently owned by institutional investors.

Shares of NASDAQ:ANCN traded up $0.22 during mid-day trading on Thursday, reaching $2.79. The stock had a trading volume of 27,261 shares, compared to its average volume of 13,544. The firm has a market cap of $20.18 million and a P/E ratio of -0.53. ANCHIANO THERAP/S has a 1 year low of $2.49 and a 1 year high of $11.50. The business has a 50 day moving average of $3.89.

ANCHIANO THERAP/S Company Profile

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.

Further Reading: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on ANCHIANO THERAP/S (ANCN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.